I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

*P*reimplantation genetic testing (PGT) is an early form of prenatal genetic diagnosis where abnormal embryos are identified, and only genetically normal embryos are used for implantation. This has become an integral part of Assisted Reproductive Technology (ART) procedures.

Historically, the development of PGT technology dates back to 1890 with Walter Heape\'s experiments of successfully transferring embryos in the Belgian Hare doe rabbits.\[[@ref1]\] Animal experiments continued through the first half of the 20^th^ Century. In 1935, Gregory Pincus, inspired by Heape\'s results, was able to culture rabbit oocytes to the metaphase stage of meiosis II. Professor Robert Edwards discovered that human oocytes required 37 hours for polar body extrusion and having timed each stage of human oocyte maturation, he led the way for human *in vitro* fertilization (IVF). Bob Edwards was the one who ideated PGT in the mid 60s. Edwards and Gardner in 1967, using euchrysine 2GNX vital staining technique, stained rabbit blastocyst sex chromatin.\[[@ref2]\] The preparation was observed under the fluorescence microscope. As this technique was potentially mutagenic, it was not compatible with embryo transfer. Hence, in 1968, they biopsied 200--300 rabbit trophoblast cells. These cells were further stained for sex chromatin. The biopsied blastocyst was implanted into a pseudopregnant female rabbit. At full term, the sex of the fetus was confirmed anatomically and histologically.\[[@ref3]\] This experiment became the basis for PGT and its application to test for genetically inherited diseases.

Steptoe and Edwards, in their Manchester Laboratory, made many attempts since 1970 onwards to establish IVF in humans. Dr. Carl Wood of the Monash IVF team in Melbourne reported the first IVF pregnancy in 1973, although it resulted in an early miscarriage. In 1976, Steptoe and Edwards published a case of ectopic pregnancy following transfer of an early blastocyst. After several failed attempts, medical history was made on July 25, 1978, with the birth of the world\'s first "test tube baby" Louis Brown.\[[@ref4]\] The reintroduction of ovarian stimulation by Trounson *et al*. in 1981 was a major breakthrough that increased the chances of pregnancy in IVF.\[[@ref5]\]

Although pregnancy rates improved with time, results of IVF for male factor infertility remained very low with failed fertilization occurring commonly as the sperm of these men did not have the ability to perform all the steps needed for fertilization.

To characterize the fertilization potential of human sperm, the hamster egg-human sperm penetration assay was developed.\[[@ref6]\] In their paper, Li *et al*. demonstrated Uehara and Yanagimachi\'s classic work in 1976 of injection of human sperm into hamster oocytes showing sperm nuclear decondensation \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref7]\] The technique of sperm microinjection was pioneered by Hiramoto in the Sea Urchin in 1962\[[@ref8]\] and by Lin in 1966 in mouse oocytes.\[[@ref9]\]

![Sperm nuclear decondensation in zona-free hamster oocyte](JHRS-11-306-g001){#F1}

The practical use of micromanipulation started in the mid 80\'s with zona drilling (ZD) and partial zona dissection (PZD) when the sperm count, motility, or morphology were low. Pioneering attempts of ZD on a mouse model were carried out by Gordon *et al*., using a micromanipulator to produce holes in the zona pellucida (ZP) of unfertilized mouse oocytes with acid Tyrode\'s solution.\[[@ref10]\] The first attempts at ZD of human oocytes for the alleviation of male infertility resulted in fertilization, however, pregnancy did not ensue in the ten couples included in this report.\[[@ref11]\]

The first live birth in the world with embryo micromanipulation techniques was reported by Ng and Bongso from Singapore, where insemination was done under the ZP.\[[@ref12]\] This micro-insemination sperm transfer technique later became popularly known as subzonal injection of sperm (SUZI).\[[@ref13]\] The earlier PZD technique did not give good results and was discontinued as it led to polyspermy, while SUZI gave better results and eventually led to the development of intracytoplasmic sperm injection (ICSI). Thus, by the end of the 1980\'s, several procedures of assisted fertilization had been developed and used where conventional IVF could not succeed. Microsurgical fertilization techniques helped to remove the barrier presented to the sperm by the ZP. Assisted hatching was pioneered by Cohen around the same time.\[[@ref14]\]

To achieve fertilization in nature, the sperm has to penetrate the cumulus cells. This is followed by zona binding and penetration, egg-sperm membrane interaction, and oocyte activation. Lanzendorf initiated sperm microinjection. However, the fertilized oocyte only went up to the pronuclear stage. He, therefore, abandoned the technique.\[[@ref15]\]

In 1992, Gianpiero Palermo, in Dr. André van Steirteghem\'s Laboratory in Brussels, created the first baby by sperm microinjection into the oocyte cytoplasm. The team called it ICSI \[[Figure 2](#F2){ref-type="fig"}\].\[[@ref16]\] This discovery got them international acclaim.

![Intracytoplasmic sperm injection -- Sperm is microinjected into the cytoplasm of the oocyte](JHRS-11-306-g002){#F2}

In India, the first ICSI baby of South Asia "Luv Singh," was created by our team at Jaslok Hospital, Mumbai, in 1994.\[[@ref17]\]

B[IOPSY]{.smallcaps} T[ECHNIQUES]{.smallcaps} {#sec1-2}
=============================================

Parallel to the development of IVF technology, many experiments were being performed on animal models for obtaining a single cell from the growing embryos *in vitro* for future genetic analysis. Wilton and Trounson from Australia demonstrated the technique of removal of one blastomere from cleavage-stage embryos in the mouse.\[[@ref18]\] In 1988, Marilyn Monk with Audrey Muggleton-Harris from UK developed the trophectoderm biopsy technique followed by Preimplantation Genetic Diagnosis (PGD) using biochemical microassay in a mouse model for Lesch--Nyhan disease.\[[@ref19]\] Yury Verlinsky\'s group demonstrated the use of the first polar body biopsy to check for a maternal unaffected gene.\[[@ref20]\] The Figures [3a](#F3){ref-type="fig"}--[c](#F3){ref-type="fig"} show human gametes and embryos undergoing cleavage stage, tropehctoderm and polar body biopsy.

![Biopsy techniques: (a) Blastomere biopsy (b) trophectoderm biopsy (c) polar body biopsy](JHRS-11-306-g003){#F3}

D[EVELOPMENT OF]{.smallcaps} M[OLECULAR]{.smallcaps} T[ECHNOLOGY]{.smallcaps} {#sec1-3}
=============================================================================

After the presentation of the Watson and Crick model of DNA in 1953, attempts to develop synthetic oligonucleotides and to sequence the genomic DNA were made. The technique of polymerase chain reaction (PCR) was introduced by Saiki *et al*. in 1985.\[[@ref21]\] This was a major breakthrough for the analysis of monogenic disorders in the field of molecular biology.

F[IRST]{.smallcaps} S[UCCESSFUL]{.smallcaps} P[REIMPLANTATION]{.smallcaps} G[ENETIC]{.smallcaps} D[IAGNOSIS]{.smallcaps} A[TTEMPTS]{.smallcaps} {#sec1-4}
===============================================================================================================================================

Successful attempts in the mouse model bore fruition in 1990, when Handyside *et al*. reported pregnancies after carrying out PGD for sex-linked disease and X-linked mental retardation on biopsied human preimplantation embryos. The PCR technique was carried out to detect male embryos free of the X-linked disease.\[[@ref22]\]

Handyside\'s group included Wilton and Delhanty with her Ph.D. student Griffin. They introduced the world\'s first PGD cases where male, female, and Turner syndrome embryos could be easily identified using the fluorescence *in situ* hybridization (FISH) technique. The biopsy was carried out by Handyside; the cells were fixed on the slide by Wilton and FISH analysis was carried out by Griffin *et al*.\[[@ref23]\] Simultaneously, Munné *et al*., from USA, applied PGD using the FISH technique for the first time using directly labeled probes.\[[@ref24]\]

With this many groups started using PGD technology for testing for aneuploidy and translocations by FISH and monogenic disorders by PCR. By 2001, Verlinsky *et al*. from Chicago reported the first successful PGD with human leukocyte antigen matching for a sib with Fanconi anemia by haplotype analysis.\[[@ref25]\] This led to the concept of "Savior Sib." Using disease-free HLA-matched embryos for implantation, the previously affected child could be cured using the transplantation of cord stem cells, and bone marrow of the unaffected baby created free of disease by PGD.

The FISH technology was further improved using different probe mixtures for 5--12 chromosome pairs in multiple rounds. It was offered to women with advanced maternal age, with a history of recurrent abortions, implantation failures as well as inherited Robertsonian or reciprocal translocations and inversions. The main limitation of the FISH technology was that only around 5--12 pairs of chromosomes could be tested for aneuploidy from a total of 23 pairs of human chromosomes. Hence, further research was initiated for developing newer techniques which could test all chromosomes for aneuploidies using a single blastomere within 24-72 hours of the biopsy.

In 1999, two different groups, Wells *et al*. and Voullaire *et al*. demonstrated the use of Comparative Genomic Hybridization (CGH) technology on human blastomeres to check for aneuploidies of all chromosomes.\[[@ref26][@ref27]\] In 2000, Voullaire *et al*. did an extensive study of 12 human embryos using CGH technique on more than 60 blastomeres. The study demonstrated the presence of partial aneuploidy as well as gain and loss of fragments of chromosomes which were not previously identified using the FISH analysis.\[[@ref28]\]

Wilton\'s group, in 2001, successfully applied PGD by CGH in a 38-year-old female with a history of primary infertility followed by an unsuccessful attempt at IVF by using FISH on IVF-PGD embryos. After testing by CGH, only one of five embryos turned out to be normal for every chromosome. This effort resulted in the birth of a healthy female child.\[[@ref29]\] Thereafter, CGH technology was offered to many couples successfully for the detection of all chromosomal aneuploidies and unbalanced translocations. The major drawback of the technology was the need for cryopreservation of embryos as several days were required for testing. The other drawback was the inability of this technology to detect triploidy or tetraploidy. Based on all these attempts and results in the first decade of this century, FISH still remained the most popular technique for the detection of aneuploidies within 24-72 hours.

In spite of these pioneering attempts, why did PGD not become popular?

Mastenbroek\'s group, in 2007, published a paper of a multicentric, randomized, controlled trial (RCT) where they compared three cycles of IVF with and without Preimplantation Genetic Screening (PGS) in women in the age group of 35--41 years. They showed that the on-going pregnancy rates and live birth rates were 10% lower in women undergoing PGS by FISH, compared to the non-PGS group in cases of advanced maternal age.\[[@ref30]\] This publication led to less use of PGS for the next few years.

The concept of better pregnancy outcome using this technology finally picked up when Munne and other scientists demonstrated its benefits.

New terminology was developed to differentiate between aneuploidy screening and detection of monogenic disorders. Aneuploidy screening was termed as "PGS" whereas testing for monogenic disorders was termed as "PGD." The aneuploidy detection using FISH was termed as version 1 (PGS v1) whereas aneuploidy detection for all 24 chromosomes has now become version 2 (PGS v2). Recently, a new term Preimplantation Genetic Testing (PGT) has been introduced. The recently modified terminology is PGT-A for aneuploidy screening, PGT-SR for structural rearrangements (translocation or inversion), and PGT-M for monogenic disorders.

Considering the difficulties in the use of FISH technology, several groups perfected the long learning curve for PGT which included perfecting embryo biopsy techniques without harming the embryo and genetic diagnosis using different molecular techniques. Different groups studied the effect of day 3 cleavage-stage biopsy and day 5 blastocyst biopsy on embryo implantation and live birth outcomes. New methods were introduced for the detection of aneuploidy of all chromosomes within 24--48 hours.

Based on Wilton\'s use of CGH technology for preimplantation diagnosis for aneuploidy, Wells *et al*. with his team published a paper in 2008 including the use of microarray and CGH platforms for the detection of aneuploidy of all 23 chromosome pairs.\[[@ref31]\] This technique was validated in 2011.\[[@ref32]\] In the same year, Wells\' group reported the first births after Preimplantation Genetic Diagnosis of structural chromosome abnormalities using array CGH (aCGH).\[[@ref33]\]

In 2013, Scott\'s group published their clinical trial showing that the biopsy of cleavage-stage embryos significantly impaired implantation potential; however, trophectoderm biopsy of blastocyst did not have any negative effect on implantation \[[Figure 4](#F4){ref-type="fig"}\].\[[@ref34]\] Capalbo *et al*. study showed that trophectoderm biopsy should be performed on all day 5, day 6, or day 7 blastocyst stage embryos to improve implantation outcome \[[Figure 5](#F5){ref-type="fig"}\].\[[@ref35]\] Several authors have shown the benefits of PGT to improve implantation rates (IRs). Dahdouh *et al*. carried out a meta-analysis of RCTs and observational studies to see whether PGS with comprehensive chromosome screening (CCS) improved clinical IR and sustained IR (beyond 20 weeks) compared with routine care for embryo selection in IVF cycles. They concluded that PGS with the use of CCS technology increases clinical and sustained IRs, thus improving embryo selection particularly in patients with normal ovarian reserve \[[Figure 6](#F6){ref-type="fig"}\].\[[@ref36]\] Other studies have shown an improvement in ICSI outcome with PGT.\[[@ref37]\]

![Day 3 versus day 5 biopsy. Implantation rates following a randomized paired analysis of the effects of cleavage-stage and blastocyst-stage biopsies on embryo reproductive potential. Sustained implantation and delivery of the biopsied embryo were significantly reduced compared with its control sibling, when the biopsy was performed on day 3 at the cleavage-stage (McNemar Chi-square: *P* \< 0.03). A similar paired analysis demonstrated that the developmental potential of embryos undergoing trophectoderm biopsy at the blastocyst stage was equivalent to the nonbiopsied control sibling](JHRS-11-306-g004){#F4}

![Day 5, day 6, and day 7 biopsies should be included for preimplantation genetic testing analysis. There is no significant difference between euploidy/aneuploidy rates in day 5, day 6, and day 7 blastocysts](JHRS-11-306-g005){#F5}

![Meta-analysis of randomized controlled trials on preimplantation genetic screening with comprehensive chromosome screening versus routine care](JHRS-11-306-g006){#F6}

After 2010, several other methods were developed for CCS such as single-nucleotide polymorphism (SNP) Testing, Quantitative Real-Time PCR (QT-PCR), and next-generation sequencing (NGS). Furthermore, the concept of euploid Single Embryo Transfer (eSET) was introduced. Forman *et al*. compared CCS-eSET group with non-CCS with SET group and showed higher on-going pregnancy rate (55% vs. 42%) and lower miscarriage rate (11% vs. 25%) in CCS-eSET group. They also showed that, in CCS-eSET group, overall IR was also higher compared to non-CCS with SET group irrespective of maternal age \[[Figure 7](#F7){ref-type="fig"}\].\[[@ref38]\] In 2013, several groups showed the successful use of NGS technology for PGT-A\[[@ref39]\] and monogenic disorders.\[[@ref40]\] NGS has become the most popular method due to the shorter testing time and cost-effectiveness. Recent studies by different groups for PGT-A outcomes comparing aCGH versus NGS showed marginally improved results with NGS with eSET.\[[@ref41]\] Although there are several advantages of these new techniques for aneuploidy detection, due to the limitation of their sensitivity, FISH is still used for telomeric translocations and inversions.\[[@ref42]\]

![Overall implantation rate increases in comprehensive chromosome screening with eSET cases independent of age](JHRS-11-306-g007){#F7}

The current indications for PGT include repeated implantation failures, repeated pregnancy loss, advanced maternal and paternal age, male factor infertility, and genetic disorders in the parents including mosaicism of sex chromosomes, structural rearrangements, and monogenic genetic diseases. Scott *et al*. published a paper in 2013 showing the analysis of an RCT. The trial showed that with CCS and fresh blastocyst transfer, sustained IR was significantly higher in the CCS group (66%) compared to control non-CCS group (48%). It also showed a higher delivery rate per cycle in CCS group (85%) compared to control non-CCS group (68%).\[[@ref43]\]

B[ENEFITS OF]{.smallcaps} P[REIMPLANTATION]{.smallcaps} G[ENETIC]{.smallcaps} T[ESTING FOR]{.smallcaps} A[NEUPLOIDY]{.smallcaps} (PGT-A) {#sec1-5}
========================================================================================================================================

Chromosomal aneuploidies are one of the major causes of infertility and maternal age-related reduced fertility potential. More than 70% of spontaneous miscarriages are due to chromosomal aneuploidies. PGT-A helps to shorten the time to a viable pregnancy by reducing the need of multiple IVF cycles. Euploid embryo transfer results in highest pregnancy rates and live birth rates reducing miscarriage risk independent of maternal age.

H[OW]{.smallcaps} M[ANY]{.smallcaps} P[REIMPLANTATION]{.smallcaps} G[ENETIC]{.smallcaps} T[ESTED]{.smallcaps} E[MBRYOS]{.smallcaps} S[HOULD BE]{.smallcaps} T[RANSFERRED]{.smallcaps}? {#sec1-6}
======================================================================================================================================================================================

Based on the recommendations given by the Practice Committee of the American Society for Reproductive Medicine (ASRM) and the Practice Committee of the Society for ART (SART) published in April 2017, single euploid cleavage-stage or blastocyst embryo should be transferred irrespective of the age group.\[[@ref44]\]

However, PGT has its limitations under certain circumstances.\[[@ref42]\] Subtelomeric deletions, mosaicism, small structural rearrangements, microdeletions, and microduplications may pose challenges. Furthermore, experienced laboratory personnel in IVF and genetics are important for a patient\'s success.

M[ITOCHONDRIAL]{.smallcaps} DNA C[ONTENT]{.smallcaps} {#sec1-7}
=====================================================

One of the new modalities for enhancing success is the evaluation of the mitochondrial DNA (mtDNA) content of the embryo.\[[@ref45]\] The concept is that a high mtDNA copy number in euploid embryos is indicative of lower embryo viability and implantation.\[[@ref46]\] This is still not the mainstay in the diagnosis of healthy energetic embryos. Victor *et al*. did not show any significant difference in mitochondrial levels in blastocysts irrespective of age, ploidy, or implantation potential.\[[@ref47]\] As opposed to this, Fragouli *et al*. showed that no pregnancies resulted from blastocysts with elevated mtDNA levels.\[[@ref48]\]

M[OSAIC]{.smallcaps} E[MBRYO]{.smallcaps}: T[O]{.smallcaps} T[RANSFER OR]{.smallcaps} N[OT TO]{.smallcaps} T[RANSFER]{.smallcaps}! {#sec1-8}
==================================================================================================================================

Embryonic chromosomal mosaicism is a condition in which more than one cell line is present, where one has a normal chromosomal constituent and others have abnormalities in chromosome number. It is assumed that mosaicism has adverse effects to the implantation and development of the embryo. Munné *et al*. reported that 41% of mosaic embryos resulted in on-going implantation. Complex mosaic blastocysts and embryos with \>40% abnormal cells had a lower on-going IR than other mosaics.\[[@ref49]\] Spinella *et al*. in their study showed that the extent of mosaicism influences the success rate of IVF.\[[@ref50]\] Here, they used mosaic embryos with low aneuploidy percentage for implantation with higher chances of healthy live births compared to embryos with a higher percentage of mosaicism. Kushnir *et al*., from their study, concluded that there was a higher on-going pregnancy rate and a lower miscarriage rate when euploid embryos were used for implantation compared to the use of mosaic embryos. However, there was no significant difference in the on-going pregnancy rates or miscarriage rates among mosaic embryo transfers at any threshold of aneuploidy, and the degree of trophectoderm mosaicism was a poor predictor of on-going pregnancy and miscarriage.\[[@ref51]\]

N[EWER]{.smallcaps} T[ECHNOLOGY IN]{.smallcaps} P[REIMPLANTATION]{.smallcaps} G[ENETIC]{.smallcaps} T[ESTING]{.smallcaps}-M: K[ARYOMAPPING]{.smallcaps}: B[EYOND]{.smallcaps} S[TANDARD]{.smallcaps} N[EXT]{.smallcaps}-G[ENERATION]{.smallcaps} S[EQUENCING]{.smallcaps} {#sec1-9}
=========================================================================================================================================================================================================================================================================

In 2010, Alan Handyside with his group described the concept of karyomapping. It is genome-wide parental haplotyping using high-density SNP genotyping. Here, a linkage-based diagnosis is carried out for any single-gene defect. By knowing the genotyping of the parents and a close relative of known disease status, generally a previously affected child, this technology eliminates the need for customized test development. Karyomapping identifies informative loci for each of the four parental haplotypes across each chromosome and maps the inheritance of these haplotypes and the position of any crossovers in the proband as well as in the preimplantation embryos. Thus, it identifies the embryo-carrying normal chromosome copies.\[[@ref52]\]

N[ONINVASIVE]{.smallcaps} P[REIMPLANTATION]{.smallcaps} G[ENETIC]{.smallcaps} T[ESTING]{.smallcaps} T[ECHNIQUES]{.smallcaps} {#sec1-10}
============================================================================================================================

As embryo biopsy is an invasive procedure, efforts are being made to find different embryonic samples which do not require embryo biopsy. One of the novel approaches is the use of noninvasive PGS. Palini *et al*., in 2013, attempted isolation of cell-free DNA from blastocoel fluid (BF) for aneuploidy testing using the microarray technique.\[[@ref53]\] Gianaroli *et al*. compared ploidy status of BF with trophectoderm cells, whole embryo, polar body, and/or blastomere and concluded that BF could be used as an alternative source for aneuploidy testing.\[[@ref54]\] Lane *et al*. tried aneuploidy detection using DNA isolated from the spent culture medium.\[[@ref55]\] Kuznyetsov *et al*. tried a combination of blastocyst culture-conditioned medium (BCCM) and BF to obtain sufficient embryonic DNA for whole genome amplification and accurate aneuploidy screening.\[[@ref56]\] All these approaches are still under research.

O[UR]{.smallcaps} E[XPERIENCE WITH]{.smallcaps} P[REIMPLANTATION]{.smallcaps} G[ENETIC]{.smallcaps} T[ESTING]{.smallcaps} {#sec1-11}
=========================================================================================================================

We initiated PGT at Jaslok Hospital, Mumbai, in 1999, using the FISH technique.\[[@ref57]\] Ours was the first center in India to offer PGT by FISH for various genetic disorders in the early 2000s.\[[@ref58][@ref59][@ref60][@ref61]\] With PGT-A by FISH, our clinical pregnancy rate was 36% per patient and 28% per cycle. Our team reported the first live births in India for a Robertsonian\[[@ref62]\] and reciprocal translocation,\[[@ref63]\] inversion with a cryptic translocation picked up on pre-PGT-A workup\[[@ref64]\] and pregnancy after PGT for a complex translocation.\[[@ref65]\] Currently, we use the NGS platform to offer PGT-A. In our latest series of 197 cycles, our pregnancy rate was 40%. We have also successfully carried out PGT-M for the first time, in India, for genetic disorders such as Duchenne muscular dystrophy, neurofibromatosis, sickle cell anemia, Leigh syndrome, retinoblastoma, hereditary inclusion body myopathy, cardiac disorders, and carriers of BRCA1.\[[@ref66]\] We recently reported for the first time, in India, twin babies born free of the autosomal dominant BRCA1 mutation to a woman who was a BRCA1 mutation carrier\[[@ref67]\] and had familial hereditary cancer syndrome in herself and her close family. We also have several pregnancies in couples carrying mutations for beta thalassemia.

C[ONCLUSION]{.smallcaps} {#sec1-12}
========================

From the above review, we can conclude that PGT is a major diagnostic tool to prevent transmission of any known genetic disorder. It also helps in populations which are at high risk of having babies with certain genetic aberrations. PGT reduces the trauma of multiple failed IVF cycles, early miscarriages, and helps in cases of advanced maternal age to prevent the birth of a syndromic child. PGT-M protects the child from inherited monogenic disorders. With the concept of savior sibling, PGT-M is useful in some of the hematological disorders to cure an affected child.

PGT technology should be integrated into ART to offer the best outcomes to patients. However, this technology should be used judiciously, and its pitfalls should be understood.
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